Report Summary 1. Report Industry Investment Rating No information provided regarding the industry investment rating. 2. Core Viewpoints - The company is in a favorable position in 2025 Q1, with a 38.19% increase in net profit due to low - oscillating crude oil prices supporting costs and the recovery of downstream chemical product demand [31]. - The company aims to build and promote an AI development strategy on the basis of the "1 + N" strategy, striving to become a world - class energy and chemical enterprise in the AI era [27]. - The company expects future crude oil prices to continue to fluctuate at current levels, which is beneficial for raw material cost support and potentially improving profitability [31]. 3. Summary by Directory 3.1. Research Basic Situation - The research object is Orient Shenghong, belonging to the chemical fiber industry. The reception time was May 20, 2025, and the company's reception staff included the deputy chairman, independent directors, and other executives [16]. 3.2. Detailed Research Institutions - The research institutions included investors who participated in the company's 2024 annual online performance briefing online [19]. 3.3. Research Institution Proportion No information provided. 3.4. Main Content Materials - **Company Achievements in 2024** - The company expanded its industrial layout. The devices for products such as PETG, nitrile latex, and EC/DMC were successfully started up at one time. The POSM and polyol devices of the chemical new material project were fully put into production. The photovoltaic - grade EVA increased by 200,000 tons in production capacity, reaching 500,000 tons/year [24]. - The company had significant innovation achievements, including building the world's first "from carbon dioxide to polyester fiber" industrial chain, winning multiple awards, and having some subsidiaries recognized as champions in the manufacturing industry [25][26]. - The company practiced green and low - carbon development, signing a clean power supply cooperation agreement and launching green product brands [27]. - **Q&A Session** - **EVA and POE Products**: As of the end of 2024, the company's EVA production capacity was 500,000 tons/year, ranking high in the industry in terms of scale and market share. The 100,000 - ton/year POE industrial device is under construction as planned. The company will use its strategic cooperation with downstream photovoltaic film leading enterprises to strengthen market promotion and customer expansion [28]. - **"1 + N" Strategy**: The company has formed a vertically integrated industrial chain layout. The "1 + N" pattern will enable the full linkage of refining, new energy and new materials, and polyester chemical fiber businesses in the future [30][31]. - **Profit and Market Outlook**: The company expects future crude oil prices to fluctuate, which is beneficial for cost support. It will optimize product structure, adjust pricing, and manage inventory according to market conditions [31][32]. - **Recycled Polyester Fiber**: The company's recycled polyester fiber production capacity is about 600,000 tons/year, and its downstream customers cover more than 30 well - known brands [32]. - **Tariff Impact**: In 2024, the company's overseas revenue was 6.753 billion yuan, accounting for about 5% of total revenue. The import and export volume to the US was almost zero, so future US tariff increases would have no direct impact [33]. - **Crude Oil Procurement**: The company's crude oil mainly comes from the Middle East. It formulates procurement plans based on price fluctuations and production plans and conducts appropriate crude oil futures hedging [33]. - **Capital Expenditure**: In 2024, capital expenditure was mainly for the construction of projects such as EVA, POE, POSM, and polyether polyol. The peak of capital expenditure has passed, and it is expected to decline gradually in the future [33]. - **R & D Investment**: In 2024, the company's R & D investment was 6.35 billion yuan, a year - on - year increase of 11.2%. It has multiple innovation platforms and has achieved many technological innovation results [33][34][35].

Report Summary 1. Report Industry Investment Rating There is no information provided regarding the industry investment rating in the given content. 2. Report's Core View - The report focuses on the in - depth research of Anxu Bio, a biotech company in the medical device industry. It highlights the company's comprehensive strength, including its strong R & D capabilities, diverse product lines, and strategic layout for future development. Anxu Bio aims to become a leading enterprise in the international in - vitro diagnostic industry through continuous innovation and market expansion [23][24]. 3. Summary by Related Catalogs 3.1. Research Basic Situation - The research object is Anxu Bio, belonging to the medical device industry. The reception time was on May 20, 2025. The listed company's reception staff included the company's chairman and general manager Ling Shisheng, board secretary Han Jun, financial controller Kang Min, and independent director Zhang Guobiao [16]. 3.2. Detailed Research Institutions - The relevant personnel participated in the "2024 Annual Report and 2025 First - Quarter Performance Briefing" [19]. 3.3. Research Institution Proportion There is no specific information provided about the research institution proportion in the given text. 3.4. Main Content Data 3.4.1. Company Basic Situation Introduction - Anxu Bio was founded in 2008 and went public on the Science and Technology Innovation Board in November 2021. It is a high - tech biotech enterprise integrating R & D, production, and sales of in - vitro diagnostic reagents, POCT instruments, and biological raw materials. It has achieved an integrated industrial chain layout from upstream core biological raw materials to diagnostic reagents and instruments [23]. - The company has eight major fields of POCT reagents and related supporting instruments, covering drug testing, infectious disease testing, etc., and its products are sold in more than 150 countries and regions. It also actively strategically layouts in the pharmaceutical field, such as third - party medical testing laboratories, pet health management, and family health management [23][24]. - In the future, the company will continue to increase investment in R & D and production of biological raw materials, improve the performance of POCT reagents and instruments, and focus on both international and domestic markets to become a leading enterprise in the international in - vitro diagnostic industry [24]. 3.4.2. Q&A Session Main Content - **Financial Performance**: In 2024, the company's operating income was 540.6985 million yuan, net profit attributable to the parent company was 192.2953 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 37.8979 million yuan. In the first quarter of 2025, the operating income was 115.2965 million yuan, net profit attributable to the parent company was 34.0296 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 22.7603 million yuan [25]. - **R & D Breakthroughs and Advantages**: The company has built nine technology platforms, forming a trinity industrial chain layout of raw materials, reagents, and instruments. In 2024, it added 44 authorized patents (including 13 invention patents), with a total of 305 authorized patents, and added 606 international and domestic certifications, with a total of 1580 certifications, including EU CE and US FDA [25]. - **Business Expansion**: The company promotes the iteration of core products, builds a diversified product matrix, and explores performance growth potential in fields such as pet health management, family health management, and medical testing laboratories, advancing the Anxu Bio medical and health ecosystem strategy [26]. - **Future Profit Growth Drivers**: The company will focus on technological innovation, increase R & D investment, explore frontier technology fields, continue to expand overseas markets while increasing efforts in the domestic market, and consider expanding medical and health - related business through cooperation, investment, or mergers and acquisitions [26]. - **GluMate App**: With the rising global prevalence of chronic diseases, GluMate is launched to improve the health management of chronic disease patients. It aims to transform from single - detection to full - cycle service and build a chronic disease monitoring product system centered on GluMate, providing intelligent and personalized chronic disease management solutions [27]. - **2024 Dividend Policy**: In 2024, the company plans to distribute a cash dividend of 8 yuan per 10 shares (tax - included) to all shareholders, with a total cash dividend of 152.499366 million yuan (including the interim dividend), accounting for 79.30% of the net profit attributable to listed company shareholders in the 2024 consolidated statements [28]. - **Market Expansion Measures and Achievements**: The company adheres to the "international + domestic" dual - wheel drive strategy. Overseas, its products are sold in more than 150 countries and regions, and it participates in well - known exhibitions to enhance brand influence. Domestically, it has obtained new product registration certificates and promoted brand sales through online and offline channels. It has also established subsidiaries in Singapore, the United States, and Europe to optimize the global marketing network [28][29].

Group 1: Report Overview - The report is about a research on Tongde Chemical Industry, a company in the chemical products industry, with a research date of May 20, 2025 [1][2][17] Group 2: Research Basic Information - Research object: Tongde Chemical Industry [17] - Industry: Chemical products [2][17] - Reception time: May 20, 2025 [17] - Company reception staff: Chairman Zhang Hong, Financial Controller Jin Fuchun, and Board Secretary Zhang Dong [17] Group 3: Detailed Research Institutions - The reception objects include investors' online questions and others [20] Group 4: Core Views - The civil explosive industry adheres to innovation - driven development, promotes technological progress, digital technology empowerment, supply - side structural reform, and green development [25] - Tongde Chemical Industry has grown into an advantageous backbone civil explosive enterprise integrating scientific research, production, sales, distribution, blasting, and trade, with core competitiveness in location, safety, business model, and operation management [25] - The company is taking measures to improve performance, reduce costs, and enhance competitiveness, such as technological transformation, optimizing the supply chain, and increasing R & D investment [24][26][27] Group 5: Main Content Details R & D and Technological Achievements - In 2024, the company's R & D investment was 1.29539 million yuan, accounting for 2.38% of operating income. It has carried out cooperation with research institutions, achieved phased results in technologies like continuous production of emulsion explosives and intelligent monitoring and control of blasting sites, and launched new products [24] 2025 Q1 Performance - In Q1 2025, the company's operating income was 112 million yuan, a year - on - year decrease of 27.67%, and the net profit attributable to shareholders was 10.3067 million yuan, a year - on - year decrease of 51.51%, mainly due to the technical transformation of production lines [24] Industry Development and Company Status - The civil explosive industry is developing towards innovation, digitalization, and green development. The company has advantages in various aspects and improved production safety and efficiency through technical transformation [25] Cost - Reduction and Efficiency - Enhancement Measures - The company will optimize the production process, use intelligent production technology, strengthen R & D, and cooperate with suppliers to reduce costs [26] Market Share Strategy - The company provides customized services to large customers, optimizes the supply chain, and focuses on high - value - added products to expand market share [27] Response to Audit Issues - The company acknowledges the audit report's issues and will take measures such as government - coordinated debt relief, business recovery, project investment, and management improvement [30][31][33] New Project Progress - The PBAT new material industrial chain integration project with a total investment of about 3.5 billion yuan has completed the main project construction, and the company is seeking investors for this year's production [34]

1. Reported Industry Investment Rating - No information provided 2. Core View of the Report - The motorcycle industry in China shows steady growth, with intensified domestic competition and continuous growth in foreign exports. The trend of Chinese motorcycles going global is positive, and domestic motorcycle brands have greater structural opportunities in overseas markets than in total volume [24]. - The company aims to achieve revenue of over 19 billion yuan in 2025, and plans to conduct mid - term dividends in 2025 under eligible conditions [27]. - The company will work with its controlling shareholder to optimize supply chain management and enhance supply chain synergy to strengthen market competitiveness [28]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - The research object is Loncin General, belonging to the transportation equipment industry. The reception time was May 20, 2025. The listed company's reception staff included the chairman, general manager, independent directors, board secretary, and financial controller [17]. 3.2. Detailed Research Institutions - The reception objects include investors and others [20]. 3.3. Research Institution Proportion - No information provided 3.4. Main Content Data - **Motorcycle Industry Development**: In 2024, China's fuel motorcycle sales reached 16.4562 million units, a year - on - year increase of 12.99%. Domestic sales were 8.9065 million units, a year - on - year decrease of 16.56%, and export sales were 11.0163 million units, a year - on - year increase of 26.72% [24]. - **Popular Products of Wujie**: SR250GT redefined the leisure sports scooter market; CU525 became the king of the same - level cruising motorcycles; DS900X had annual sales of over 10,000 units, accounting for over 95% of the total export volume of motorcycles above 800cc in China. New products such as CU250 and RR660S were also launched [24][25]. - **Reasons for Low Domestic Sales of Wujie 900DS**: The most popular product categories in the domestic market are cruising, sports, and scooter models. The domestic leisure and entertainment motorcycle market is still in the development stage, and the sales volume of large - displacement motorcycles is mainly concentrated in the 400 - 600cc range [26]. - **Business in the US and Risk Resistance**: The company's motorcycle exports are mainly to Europe, South America, and Africa. Exports to the US are mainly general machinery products, accounting for less than 7% of total revenue. The company will expand market share in multiple regions and take measures such as "going global in groups" with the supply chain and optimizing overseas manufacturing plant layouts [26]. - **Future Profit Growth Drivers**: The company will follow the strategic path of "product going global → brand going global → production capacity going global", increase the proportion of self - owned brand revenue, optimize the product sales structure, improve operational efficiency, and strengthen risk management [26]. - **2025 Business Plan**: The company will adhere to the business philosophy of "optimizing the existing and breaking through in the new", with a guiding ideology to promote high - quality and sustainable development, and strive to achieve revenue of over 19 billion yuan [26][27]. - **2025 Mid - term Dividend Consideration**: The company has proposed to the general meeting of shareholders to authorize the board of directors to formulate a mid - term dividend plan for 2025 and plans to conduct mid - term dividends under eligible conditions [27]. - **Competition and Supply Chain Integration**: The new controlling shareholder and actual controller of the company have promised to resolve the issue of competing businesses. The company will optimize supply chain management with the controlling shareholder to enhance supply chain synergy [28].

1. Report Industry Investment Rating - No relevant information provided 2. Core Viewpoints of the Report - The company's programmatic advertising business has achieved significant technological improvements, with a 7 - fold increase in inference efficiency, over 30% reduction in total task execution time, and about 25% reduction in computing resource costs in the prediction algorithm, providing strong technical support for its large - scale growth [24] - The company's business covers more than 200 countries and regions globally, which can disperse regional risks caused by tariffs [26] - The company has achieved the commercialization and application of a series of AI - driven products and is committed to developing and practicing in sub - application layers such as AI marketing content production, data analysis, and intelligent automated placement [26] - In 2024, the company's revenue was 2.547 billion yuan, with a year - on - year increase of 18.83%. In the first quarter of 2025, the revenue was 929 million yuan, with a year - on - year increase of 93.18% [28] - In the next 3 - 5 years, the company's business growth points will come from expanding new customers and industries, deepening media cooperation, and driving through technological products [29] 3. Summary According to the Directory 3.1. Research Basic Situation - Research object: Yidian Tianxia - Industry: Internet services - Reception time: May 20, 2025 - Reception personnel: General Manager Wu Ying, Board Secretary Wang Ping, Financial Controller Zheng Zhengdong, Independent Director Zhang Xueyong [17] 3.2. Detailed Research Institutions - Reception object types: Investor online questions, others - Related personnel: Not specified [20] 3.3. Research Institution Proportion - No relevant information provided 3.4. Main Content Data - **Question 1**: In 2024, the programmatic advertising platform revenue increased by 210% year - on - year, but the single - customer ARPU value decreased by 29% year - on - year. The company's programmatic advertising business is the core business, and the technical improvement provides support for its growth [24] - **Question 2**: The cooperation with AppLovin is progressing smoothly. The company is in the service trade category and is not directly affected by tariffs. It has deployed in multiple emerging markets globally to disperse risks [24][26] - **Question 3**: The company has achieved the commercialization of AI - driven products and will focus on the development of sub - application layers in the future [26] - **Question 4**: The US business revenue accounts for a low proportion, and the company's business covers more than 200 countries and regions globally [27] - **Question 5**: The company attaches great importance to shareholder rights and interests, pays close attention to policy dynamics, and takes improving operating performance as the core [27] - **Question 6**: In 2024, the company's revenue and profit increased. The actual controller did not reduce holdings, and the management's reduction of holdings was for normal reasons. The company focuses on improving its core competitiveness [28] - **Question 7**: The cooperation with AppLovin is progressing smoothly [28] - **Question 8**: In the next 3 - 5 years, the company's business growth points will come from expanding new customers and industries, deepening media cooperation, and technological product drive [29] - **Question 9**: The company will continue to focus on its main business, actively explore new application fields, and use AI to empower customers to provide excellent all - link solutions for going global [31]

Group 1: Report Core Information - Reported company: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [2] - Research date: May 20, 2025 [16] Group 2: Research Basic Information - Research object: Guilin Sanjin [16] - Industry: Traditional Chinese medicine [16] - Reception time: 2025 - 05 - 20 [16] - Reception staff: Host, Chairman and President Zou Xun, Director, Vice - President and Financial Officer Xie Yuan'gang, Vice - President and Board Secretary Li Chun, Independent Director Chen Liang [16] Group 3: Detailed Research Institutions - Reception object: All investors [19] - Reception object type: Others [19] - Reception method: Network remote [19] Group 4: Main Content Big Pharmacy - Reason for loss: Store expansion leading to large expenditures [23] - Function: An important part of the company's marketing strategy, expanding sales channels and perfecting the industrial chain [23] Sales Revenue Composition - Main income sources: Most from Chinese patent medicines, some from chemical drugs of Hunan Sanjin, and some from daily - chemical health products [23] - Key varieties: First - tier varieties like Sanjin Tablets series and Watermelon Frost series; second - tier varieties like Xuanyunning and Gejie Dingchuan Capsules; third - tier varieties in market development stage with small proportion [23] Dividend Policy - 2024 annual equity distribution plan: Proposed to distribute 3.5 yuan per 10 shares, totaling 206 million yuan in cash dividends, and also disclosed the 2025 mid - term cash dividend plan [24] Watermelon Frost Toothpaste - Product series: Yayanqing, Classic Anti - inflammation, Qingyan Toothpaste, etc. [25] - Current situation: Currently building sales channels, listed and promoted in second - tier and lower cities nationwide, mainly through supermarket channels and supplemented by online sales. The overall scale is small but in the growth stage [25] - Future plan: Leverage the company's advantages to expand the market scale [25] Subsidiaries in Shanghai - Baifan Bio: Affected by the investment and financing environment, with some idle production capacity in the short - term, but business development and customer resource accumulation have increased compared to 2023 [25] - Baichuan Bio: Multiple project pipelines are in the new drug R & D stage, with only a small amount of income from technical services, small revenue scale, large R & D expenditure [25] - Measures: Control costs and expenses, optimize the personnel structure, hire professional consulting companies, optimize R & D pipelines, and focus on projects like BC006 monoclonal antibody injection [26] New Drug R & D Progress - Progress: Advancing steadily according to the plan, and relevant information will be announced when significant progress is made [26] Second and Third - tier Varieties - Growth trend: Overall growth is better than first - tier varieties. Gejie Dingchuan Capsules may continue last year's growth rate; Xuanyunning series aims for double - digit growth this year; Lamotrigine Tablets aim to reach 100 million yuan in sales this year; other varieties strive for continuous breakthroughs and high growth rates [26][27]

/ 机构调研pro小程序 DJvanbao.com 中纺标分析师会议 调研日期：2025年05月16日 调研行业：专业服务 参与调研的机构：通过网络方式参加公司2024年年度报告业绩说 明会的投资者等 洞见研报 出品 : 的問悉各行业更流企业调研情况。 LIST 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击 ...

Group 1: Research Basic Information - The research object is Qiaqia Food, belonging to the food and beverage industry, and the reception time was on May 16, 2025 [8] - The listed company's reception staff included the chairman and general manager Chen Xianbao, vice - chairman and deputy general manager Chen Qi, etc. [8] - Participating research institutions included Dongxing Securities, CITIC Securities, Tianfeng Securities, etc., as well as some fund management companies and asset management companies [2][9][10] Group 2: Core Views - The company's future development depends on product innovation and product strength, and each double - digit growth is accompanied by the emergence of a new large - scale product series [21] - The company aims to expand sales volume and increase gross profit margin through category innovation, product innovation, and channel sales service innovation, while continuously improving supply chain efficiency [17][19] Group 3: Specific Content Summaries Reasons for the decline in the company's first - quarter gross profit margin - The decline in the first - quarter gross profit margin was mainly due to the increase in sunflower seed raw material costs (affected by continuous rain in Inner Mongolia, the mold rate increased, and the output of qualified raw materials decreased, leading to price increases) and the increase in the purchase price of some nut raw materials. Product structure also had an impact [17] Scale and future plans of Sam's Club and snack retail channels - Sam's Club revenue increased by 50 - 60% last year, and the snack retail channel doubled. The company will increase investment in these channels this year [17] Plans for the third - largest product category - In the short - to - medium term, the company focuses on nuts and melon seeds. The third - largest category, such as peanuts, is in the incubation stage, and the company hopes to become a leading brand in this segment. The fresh - cut fries have achieved revenues of several million yuan in less than a year [17] Overseas development strategy for konjac products - The company first conducts trial sales overseas, leveraging its brand and channel advantages [17] Sales channels for Kui Zhen products - Kui Zhen is sold both online (e.g., its official flagship store) and offline (e.g., Sam's Club and RT - Mart's premium stores), and will continue to expand in these channels [19] Company's competitive points for nuts - The most important thing for products is quality, and for nuts, freshness must be ensured [19] Company's learning from Coca - Cola and农夫山泉 - These two companies are learning examples for Qiaqia Food in terms of products, channels, and brands. Qiaqia Food focuses more on product raw materials due to its high direct raw material cost ratio and is seeking a suitable model for itself [20] Company's view on KA direct - sales channels - The company pays attention to changes in offline retail channels, hopes that each link in the value chain can obtain reasonable profits, and will actively embrace the trend of KA direct - sales and explore a suitable cooperation model with distributors [20] Company's R & D considering population aging - The company has considered population aging in product R & D, such as nut powder products, and will develop specialized deep - processed products for the elderly. It has also launched low - GI nuts for people with sugar - control needs, and health is one of the future R & D directions [21]

Group 1: Report Overview - Reported company: Muyuan Foods Co., Ltd. [16] - Industry: Agriculture, Animal Husbandry, Feed, and Fishery [2] - Research date: May 16, 2025 [16] Group 2: Research Participants - Institutions and individuals participating in the research: Hu Peng, Dai Xuesong, Bai Xue, Bao Haibin, Zhang Tao, Liu Youzhi, Zhang Erkuan, etc. [19] Group 3: Chairman's Speech - Past decade achievements: The company has continuously improved in business, internal governance, and compliance, with shareholders' support, improved internal governance and successor systems, and emphasized compliance and social responsibility [23] - Accumulated capabilities: Product, service, industrial chain comprehensive development, and modern technology application capabilities [24] - Future plans: Strengthen pig - raising production capabilities to create greater value [25] Group 4: Cost Reduction and Future Outlook - Current cost: In April 2025, the full - cost of pig farming reached 12.4 yuan/kg, with a target of 12 yuan/kg this year, and excellent field lines can control it below 11 yuan/kg [26] - Cost reduction paths: Improve disease prevention and control, build a scientific breeding system, promote low - soybean diet technology, and apply intelligent equipment [26] - Value - added goals: Achieve a 600 - yuan cost reduction and 100 - yuan value - added per pig through an integrated industrial chain and consumer - oriented breeding [27] Group 5: Intelligent Application - Personnel training: Intelligent application is integrated into corporate culture and management, promoting experience sharing [28] - Health management: Intelligent pig houses maintain suitable temperatures, improving production indicators and reducing labor dependence [30] - Feed nutrition: Intelligent application enables precise feed formulation and reduces labor intensity [30] - Breeding: Build a high - value breeding platform to improve breeding efficiency and pig performance [30] Group 6: Slaughter and Meat Business - Business improvement: In Q1 2025, the slaughter and meat business improved significantly, and will increase investment in segmentation and R & D to meet consumer needs [31] Group 7: International Development - Motivation: Inspired by the Party's speech, aiming to share experience globally and promote the global pig - raising industry [32][33] - Plans: Cultivate international talents, pursue capital internationalization through a Hong Kong listing, and is in the early stage of internationalization [33][34] Group 8: Investor Return - Foundation: Stable operation and continuous profit are the basis for investor returns [36] - Dividend policy: Adjusted the cash - dividend ratio from 20% to 40% in 2024 - 2026, with a record - high dividend of 7.588 billion yuan in 2024 [36] - Market value management: Developed a market value management system and will adapt return plans to the company's development [36] Group 9: Debt and Capital Expenditure - Debt reduction: The asset - liability ratio has been decreasing since early 2024, and the company aims to reduce the debt by about 10 billion this year [37] - Capital expenditure: This year's capital expenditure is about 9 billion, and future expenditure will be further controlled [37]

Group 1: Report Overview - Reported industry: Food and Beverage [2] - Research object: Fuling Zhacai [16] - Reception time: May 15, 2025 [16] - Company reception staff: Company director, board secretary, deputy general manager, and financial officer Wei Yongsheng [16] Group 2: Research Institutions - Institutions participating in the research: Xingquan Fund, Huatai Securities, Taibao Asset Management, Huatai Asset Management, Tianye Fund, Huatai Insurance Asset, Xiaoyong Fund, Hundun Investment, Himalaya Capital Management, Bojun Capital, Point72 [17] - Proportion of research institutions: Fund management companies 8%, securities companies 8%, asset management companies 17%, others 58%, investment companies 8% [19] Group 3: Core Insights Market competition strategy - The pickled vegetable market is a stock competition. The company is implementing a long - term "expand categories, expand channels" strategy, developing new products, expanding emerging and catering channels, and conducting targeted blasting projects in competitive markets [23] Effect of new cellar capacity - In late 2024, about 30,000 tons of new cellars were put into use. The increase in cellar capacity helps control raw material prices. The company has purchased more green vegetables at lower prices in the past two years, reducing the proportion of semi - finished product purchases and improving cost control [23] Effect manifestation of improvement measures - After last year's research, adjustment, and implementation, the company's external targeted blasting projects have shown initial results, and internal organizational structure and business line improvements are ongoing [23] Reason for slow growth in emerging channels - The company's main channels are traditional offline channels. Although it has entered emerging channels such as e - commerce, community group - buying, and snack stores, the e - commerce channel has intense price competition, lower profit margins, and higher costs [23] Impact of white - label products on online sales - The company's products are positioned in the mid - to high - end market. White - label products do not meet consumers' growing demand for food health and safety, and the company competes by offering products in different price ranges [24] Growth of catering channels - In 2024, the catering channel grew by 30%. The company initially entered with pickled mustard products and later increased the variety of radish and pickles [24] Consideration for mergers and acquisitions - The company lacks experience in compound seasonings. The compound seasoning market has large potential, and through mergers and acquisitions, it can quickly enter the market and achieve product - channel complementarity [24] Promotion expense arrangement - The company had low promotion expenses in Q1 this year. It will increase investment in Q2 according to consumption demand and new product launches, with an expected annual increase compared to last year [25] Attempts at casual products - The company tried pickled mustard casual products in 2023 with the launch of Xiaocuikou, but has not provided large - scale promotion support [25] Effect of flexible production improvement - After internal organizational structure adjustment, the company has shortened the new product development cycle, enabling a faster response to terminal demand and customized products [25] Incentive plan - The company is promoting relevant incentive plans as needed and will announce them if there are arrangements [26]